Business Wire

Altasciences to Conduct Clinical Trial for Opioid Use Disorder Under NIH Funding

Share

Altasciences has been selected by Indivior PLC to conduct "A Phase I, Double-Blind, Placebo-Controlled, Randomized, Single Ascending Dose Study to Assess the Safety, Tolerability and Pharmacokinetics of INDV-2000 (C4X_3256) Under Fasting and Fed Conditions in Healthy Volunteers", pursuant to the National Institutes of Health (NIH) Funding Opportunity Announcement RFA-DA-19-002, dedicated to the development of medications to prevent and treat opioid use disorder and overdose. The grant was made to Indivior by the NIH in fiscal year 2019, to apply scientific solutions to reverse the national opioid crisis. In March 2018, Indivior entered into a license agreement with C4X Discovery Holdings PLC (C4X) whereby Indivior obtained exclusive global rights to develop and commercialize INDV-2000 (C4X_3256).

The first-in-human, single-ascending-dose study will be conducted in two parts — Part I: double-blind, placebo-controlled, randomized, single-ascending-dose study in fasted condition. Part II: open-label, cross-over randomized, food interaction, single-dose study, which will be given once under fasting conditions and once at completion of a standard FDA high-fat breakfast.

Altasciences offers extensive knowledge and expertise in the conduct of opioid use disorder trials and has numerous years of conducting NIH- and FDA-funded clinical studies, prior to undertaking this most recent research.

We look forward to partnering with Indivior and are proud to continue our long-standing contributions to advancements in the treatment of opioid use disorder. Since our first NIH grant award in 2012, we have consistently contributed to the body of knowledge in the field, and have helped accelerate development of these vital options for treating opioid addiction,” says Chris Perkin, Chief Executive Officer of Altasciences.

About Altasciences
Altasciences is a forward-thinking, mid-size contract research organization offering pharmaceutical and biotechnology companies of all sizes a proven, flexible approach to preclinical and early phase clinical studies, from lead candidate selection to proof of concept. For over 25 years, Altasciences has been integrating into clients’ projects to help support educated, faster, and more complete early drug development decisions. Altasciences’ full-service solutions include preclinical safety testing, clinical pharmacology, bioanalysis, program management, medical writing, biostatistics, and data management, all of which can be tailored to specific sponsor requirements. Altasciences… helping sponsors get better drugs to the people who need them, faster.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

Julie-Ann Cabana
Altasciences
913 304-4505
jcabana@altasciences.com

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

The Antera Brand Back at the Summit of Light Alloy-wheel Producers24.4.2024 15:23:00 EEST | Press release

The Antera brand makes its comeback on the world stage during the 2024 Milan Design Week with a new collection of light alloy wheels. A premium made-in-Italy brand, Antera combines timeless design, cutting-edge technology, and the determination to overcome any obstacle. Its ambassador is the football champion Roberto Baggio, who, thanks to his successful career and winning mindset, is the perfect embodiment of the Italian’s brand spirit of 'No Compromise'. The new Antera advertising campaign’s slogan, "Where instinct meets genius, the myth becomes legend", attests to the dedication, courage, and vision of a brand which is able to project itself into the future. Antera was founded in Milan in 1991 and has produced some of the most iconic models in the field, including the Type 109, a three-spoke wheel that was named as “Alloy Wheel Design of the Year 1994”. G.M.P. Group, a company specialized in the global design and production of alloy wheels, is responsible for bringing it back to its

Parse Biosciences Launches Laboratory Automation Provider Program, Collaborates with Hamilton, Opentrons Labworks, SPT Labtech24.4.2024 15:15:00 EEST | Press release

Parse Biosciences, a leading provider of accessible and scalable single cell sequencing solutions, today announced it has launched its Laboratory Automation Provider Program, enabling automation providers to readily support the adoption of Parse’s Evercode™ single cell products. By combining powerful automation with the Parse Evercode platform, customers will have unprecedented access to high-throughput single cell sequencing, enabling them to rapidly generate insights for large-scale studies. Parse’s Evercode single cell technology has enabled researchers to scale their projects to millions of cells or nuclei and has been widely adopted across oncology, immunology, neuroscience, basic research, and drug and target discovery. To facilitate scaling up these projects and to help researchers generate insights more quickly, Parse has developed automation-friendly workflows for high-throughput sample fixation, single cell barcoding, and library preparation. As key providers in the new Labor

AMGTA Releases Research on Sustainability of Powder and Wire Additive Feedstock24.4.2024 14:59:00 EEST | Press release

The Additive Manufacturer Green Trade Association (“AMGTA”) a global advocacy group focused on promoting sustainable additive manufacturing (“AM”) industry practices, announced today the preliminary results of a research project titled “Specific Energy of Metal AM Feedstock: A Comparison.” The study, commissioned by the AMGTA and conducted by Syntec Associates, a research consultancy, in partnership with Divergent Technologies, a complete modular digital factory for complex structures, evaluated three key metal AM feedstock processing approaches—gas atomization, mechanical milling (specifically ball milling), and wire drawing—to determine specific energy requirements for producing feedstock materials. The research findings highlighted that, from an energy perspective, helium gas atomization is the most sustainable method used for gas atomization for metallic powder production of commonly used alloys, followed by argon and then nitrogen. Specific energy consumption for atomization also

KnowBe4 to Acquire Egress24.4.2024 14:00:00 EEST | Press release

KnowBe4, the provider of the world’s largest security awareness training and simulated phishing platform, today announced it has entered into a definitive agreement to acquire Egress, a leader in adaptive and integrated cloud email security. Egress’ Intelligent Email Security suite provides a set of scaled, AI-enabled security tools with adaptive learning capabilities to help prevent, protect and defend organizations against sophisticated email cybersecurity threats. Further terms of the transaction were not disclosed. Organizations globally struggle to contain behavioral-based data breaches, with 74 percent of incidents involving the human element according to Verizon’s Data Breach Investigations Report. By acquiring Egress, KnowBe4 plans to deliver a single platform that aggregates threat intelligence dynamically, offering AI-based email security and training that is automatically tailored relative to risk. “The future of security is personalized AI-driven controls and real-time coac

Vantage Data Centers Expands EMEA Portfolio with First Dublin Campus Featuring Next-Generation Energy Solution24.4.2024 13:00:00 EEST | Press release

Vantage Data Centers, a leading global provider of hyperscale data center campuses, today announced its entrance into the Irish market with the development of a multi-phase data center campus (DUB1). The company will invest more than €1 billion over multiple phases to support the construction and delivery of the campus in one of the largest data center markets in Europe. The first two phases consist of 52MW of IT capacity, with the first phase expected to be operational in late 2024. Upon completion, DUB1 will mark Vantage’s 14th EMEA campus in a growing regional portfolio that spans seven countries. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240424930079/en/ Vantage Data Centers’ flagship Dublin campus will include 52MW of IT capacity to enable next-generation applications and digital transformation. (Graphic: Business Wire) The company’s flagship Ireland campus will be located approximately nine miles (15 kilometers) f

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
HiddenA line styled icon from Orion Icon Library.Eye